STUDIES IN THYROID DISEASE

甲状腺疾病研究

• 批准号: 3855372
• 负责人: J ROBBINS
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3855372
• 关键词: blood chemistry; cancer risk; combination cancer therapy; dosage; doxorubicin; human subject; human therapy evaluation; lithium; neoplasm /cancer chemotherapy; neoplasm /cancer radionuclide therapy; radiation therapy dosage; radionuclide imaging /scanning; radiosensitizer; thyroglobulin; thyroid neoplasm

Two forms of adjuvant therapy designed to improve the effectiveness of I- 131 radiation in thyroid cancer are under study. The first is lithium ion, which is used to prolong the retention of I-131 in the cancer. Preliminary findings have been described in previous annual reports. The second is the use of doxorubicin (adriamycin) as a radiosensitizing agent. To evaluate its effectiveness, we have begun to randomized study of high-risk thyroid cancer patients who receive standard I-131 therapy with or without the administration of low-dose adriamycin (10mg/m2) 30 min preceding each I-131 treatment dose. To our knowledge, this is the first attempt to randomize patients in a therapy protocol for thyroid cancer employing I-131. Other patients with negative I-131 whole body scans but elevated concentration of thyroglobulin in blood are given I-131 therapy in an attempt to localize the cancer by post-therapy scanning. Most patients have been found to have positive post-therapy scans and they are under evaluation for possible beneficial effects of the therapy.

两种形式的辅助治疗旨在提高 I- 的有效性 131 甲状腺癌的放射治疗正在研究中。 第一个是锂离子， 它用于延长 I-131 在癌症中的保留时间。 初步的 调查结果已在之前的年度报告中进行了描述。 第二个是 使用阿霉素（阿霉素）作为放射增敏剂。 评估 其有效性，我们已经开始对高危甲状腺进行随机研究 接受标准 I-131 治疗（有或没有）的癌症患者 每次 I-131 前 30 分钟给予低剂量阿霉素 (10mg/m2) 治疗剂量。 据我们所知，这是第一次尝试随机化 接受 I-131 甲状腺癌治疗方案的患者。 其他 I-131 全身扫描呈阴性但升高的患者 血液中甲状腺球蛋白浓度的 I-131 治疗 尝试通过治疗后扫描来定位癌症。 大多数患者 已发现治疗后扫描呈阳性，并且正在接受治疗 评估治疗可能的有益效果。